Allon Therapeutics

Compounds have potential to protect brain cells

Published in Pharma Law Weekly, September 27th, 2005

Two proprietary compounds of Allon Therapeutics, Inc., (NPC) have the potential to protect and repair cells of the brain and central nervous system from disease or injury, according to a study published in the August 2005 issue of the Journal of Neuroscience, published by the Washington, DC-based Society for Neuroscience.

The two proprietary compounds are NAP, from which Allon has derived its first and second products AL-108 and AL-208, and ADNF-9, from which the company has derived product candidates now undergoing preclinical studies. AL-108 is being evaluated in phase I human clinical trials as a treatment for Alzheimer disease. AL-208 is being evaluated in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2005-09-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry